TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

DEXEDRINE SPANSULE

DEXTROAMPHETAMINE SULFATE
Approved 1976-08-02
1
Indication
--
Phase 3 Trials
49
Years on Market

Details

Status
Prescription
First Approved
1976-08-02
Routes
ORAL
Dosage Forms
CAPSULE, EXTENDED RELEASE

Companies

Active Ingredient: DEXTROAMPHETAMINE SULFATE

DEXEDRINE SPANSULE Approval History

Loading approval history...

What DEXEDRINE SPANSULE Treats

2 indications

DEXEDRINE SPANSULE is approved for 2 conditions since its original approval in 1976. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Narcolepsy
  • Attention Deficit Hyperactivity Disorder
Source: FDA Label

DEXEDRINE SPANSULE Boxed Warning

ABUSE, MISUSE, AND ADDICTION DEXEDRINE has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DEXEDRINE, can result in overdose and death [see Overdosage ] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing DEXEDRINE, assess each patient’s risk for abuse, misuse, and addiction. Educate patients...

Drugs Similar to DEXEDRINE SPANSULE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ADDERALL XR 10
AMPHETAMINE ASPARTATE
2 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity DisorderNarcolepsy
ADDERALL XR 15
AMPHETAMINE ASPARTATE
2 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity DisorderNarcolepsy
ADDERALL XR 20
AMPHETAMINE ASPARTATE
2 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity DisorderNarcolepsy
ADDERALL XR 25
AMPHETAMINE ASPARTATE
2 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity DisorderNarcolepsy
ADDERALL XR 30
AMPHETAMINE ASPARTATE
2 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity DisorderNarcolepsy
ADDERALL XR 5
AMPHETAMINE ASPARTATE
2 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity DisorderNarcolepsy
AMPHETAMINE SULFATE
AMPHETAMINE SULFATE
2 shared
PRINSTON INC
Shared indications:
NarcolepsyAttention Deficit Hyperactivity Disorder
DEXTROAMPHETAMINE SULFATE
DEXTROAMPHETAMINE SULFATE
2 shared
SPECGX LLC
Shared indications:
NarcolepsyAttention Deficit Hyperactivity Disorder
DYANAVEL XR 10
AMPHETAMINE
2 shared
TRIS PHARMA INC
Shared indications:
NarcolepsyAttention Deficit Hyperactivity Disorder
DYANAVEL XR 15
AMPHETAMINE
2 shared
TRIS PHARMA INC
Shared indications:
NarcolepsyAttention Deficit Hyperactivity Disorder
DYANAVEL XR 20
AMPHETAMINE
2 shared
TRIS PHARMA INC
Shared indications:
NarcolepsyAttention Deficit Hyperactivity Disorder
DYANAVEL XR 5
AMPHETAMINE
2 shared
TRIS PHARMA INC
Shared indications:
NarcolepsyAttention Deficit Hyperactivity Disorder
EVEKEO
AMPHETAMINE SULFATE
2 shared
AZURITY
Shared indications:
NarcolepsyAttention Deficit Hyperactivity Disorder
METHYLIN
METHYLPHENIDATE HYDROCHLORIDE
2 shared
SPECGX LLC
Shared indications:
Attention Deficit Hyperactivity DisorderNarcolepsy
RITALIN
METHYLPHENIDATE HYDROCHLORIDE
2 shared
Novartis
Shared indications:
Attention Deficit Hyperactivity DisorderNarcolepsy
ADZENYS XR-ODT
AMPHETAMINE
1 shared
NEOS THERAPS
Shared indications:
Attention Deficit Hyperactivity Disorder
APTENSIO XR
METHYLPHENIDATE HYDROCHLORIDE
1 shared
RHODES PHARMS
Shared indications:
Attention Deficit Hyperactivity Disorder
ARYNTA
LISDEXAMFETAMINE DIMESYLATE
1 shared
AZURITY
Shared indications:
Attention Deficit Hyperactivity Disorder
AZSTARYS
DEXMETHYLPHENIDATE HYDROCHLORIDE
1 shared
COMMAVE THERAP
Shared indications:
Attention Deficit Hyperactivity Disorder
CONCERTA
METHYLPHENIDATE HYDROCHLORIDE
1 shared
Johnson & Johnson
Shared indications:
Attention Deficit Hyperactivity Disorder
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DEXEDRINE SPANSULE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

DEXEDRINE is indicated in: Narcolepsy Attention Deficit Disorder with Hyperactivity As an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be pres...

⚠️ BOXED WARNING

WARNING: ABUSE, MISUSE, AND ADDICTION DEXEDRINE has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DEXEDRINE, can result in overdose and death [see Overdosage ] , and this risk i...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.